Abstract: The novel compound 5-fluoro-2[[(4-cyclopropylmethoxy-2-pyridinyl) methyl]sulfinyl]-1H-benzimidazole and physiologically acceptable salts thereof as well as intermediates, pharmaceutical compositions containing the compound as active ingredient, and the use of the compound in medicine.

Abstract: The present invention relates to metoprolol succinate, a new therapeutically active compound, and pharmaceutical preparations comprising this new compound.

Abstract: Controlled release preparation containing a number of beads comprising a salt of metoprolo as the main soluble component, a method for the production thereof and the use in the treatment of cardiovascular disorders.

Abstract: Preparation giving a controlled and extended release of both a dihydropyridine, e.g. felodipine and a .beta.-adrenoreceptor antagonist, namely metoprolol as well as a method for the manufacture of the new preparation.

Abstract: Controlled release preparation containing a number of insoluble beads applied with one or more pharmaceutically active compounds, a method for the production thereof and the use in a treatment where a controlled release of a pharmaceutically active compound is needed.

Abstract: Pharmaceutical preparation containing an acid labile compound together with an alkaline reacting compound or an alkaline salt of an acid labile compound optionally together with an alkaline compound as the core material, one or more subcoating layers comprising inert reacting compounds which are soluble or rapidly disintegrating in water, or polymeric, water soluble filmforming compounds, optionally containing pH-buffering alkaline compounds and an enteric coating as well as a process for the preparation thereof and the use in the treatment of gastrointestinal diseases.

Abstract: An extended release perparation of an active compound with very low solubility containing the active compound dissolved or dispersed in a semi-solid or liquid non-ionic solubilizer and whereby the amount by weight of the solubilizer is at least equal to the amount by weight of the active compound as well as a process for the preparation thereof.

Abstract: Pharmaceutical preparation containing omeprazole together with an alkaline reacting compound or an alkaline salt of omeprazole optionally together with an alkaline compound as the core material, one or more subcoating layers comprising inert reacting compounds which are soluble or rapidly disintegrating in water, or polymeric, water soluble filmforming compounds, optionally containing pH-buffering alkaline compounds and an enteric coating as well as a process for the preparation thereof and the use in the treatment of gastrointestinal diseases.

Abstract: A method for the preparation of 2,3,5-trimethylpyridine and some of its derivatives.

Abstract: A process for the preparation of an aryloxypropanolamine of the formulaAr--OCH.sub.2 CH(OH)CH.sub.2 NH--R Iwherein Ar is a carbocyclic or heterocyclic aromatic group and R is an alkyl or substituted alkyl group having 1 to 6 carbon atoms, characterized in subjecting a compound of the formula ##STR1## to oxidative cleavage to a dialdehyde of the formula ##STR2## which is then made subject to reduction, amination, acetal hydrolysis, and, where required, removal of a nitrogen protective group, to the formation of a compound of formula I, or an acid addition salt thereof, a compound of formula II and the preparation thereof from mannitol.

Abstract: Peptides wherein an amide bond is replaced by nonhydrolyzable isosteric linkage are disclosed as thrombogenic inhibitors.

Abstract: A pharmaceutical preparation containing as active ingredient a compound of the formula ##STR1## or a therapeutically acceptable salt thereof in which formula R.sup.1 and R.sup.2 are the same or different and each selected from the group consisting of H, CF.sub.3, NO.sub.2, --COOCH.sub.3, --COOC.sub.2 H.sub.5, alkyl containing 1-7 carbon atoms, halogen, alkoxy, containing 1-5 carbon atoms, and alkanoyl containing 1-4 carbon atoms;R is selected from the group consisting of H, alkanoyl containing 1-4 carbon atoms, and carboalkoxy containing 2-6 carbon atoms; andR.sup.3, R.sup.4 and R.sup.5, which are the same or different, are each selected from the group consisting of H, CH.sub.3, C.sub.2 H.sub.5, OCH.sub.3, OC.sub.2 H.sub.5, OCH.sub.2 CH.sub.2 OCH.sub.3, and OCH.sub.2 CH.sub.2 OCH.sub.2 CH.sub.3 ; provided that(a) at least one of R.sup.3, R.sup.4 and R.sup.5 is selected from the group consisting of CH.sub.3, C.sub.2 H.sub.5, OCH.sub.3, OC.sub.2 H.sub.5, OCH.sub.2 CH.sub.2 OCH.sub.3, and OCH.sub.2 CH.sub.2 OCH.

Abstract: Novel salts of omeprazole with Li.sup.+, Na.sup.+, K.sup.+, Mg.sup.2+, Ca.sup.2+, Ti.sup.4+, N.sup.+ (R.sup.1).sub.4 or ##STR1## as cation; processes for their preparation thereof, pharmaceutical compositions containing such salts and their use in medicine.

Abstract: Novel compounds of the formula IIIa ##STR1## wherein R.sup.1a, R.sup.2a, R.sup.3a and R.sup.4a are the same or different and are hydrogen, an alkyl, alkoxy optionally completely or predominantly substituted by fluorine or chlorine, halogen, --CN, --CF.sub.3, --NO.sub.2, --COR, --COOR, aryl, aryloxy or arylalkoxy group, or adjacent groups R.sup.1a, R.sup.2a, R.sup.3a and R.sup.4a together with the adjacent carbon atoms in the benzimidazole ring form a 5-, 6- or 7-membered monocyclic ring or a 9-, 10- or 11-membered bicyclic ring, which rings may be saturated or unsaturated and may contain 0-3 heteroatoms selected from N and O and which rings may be optionally substituted with 1-4 substitutents selected from alkyl groups with 1-3 carbon atoms, halogen preferably F or Cl, alkylene radicals containing 4-5 carbon atoms giving spiro compounds, or two or four of these substituents together form one or two oxy groups ##STR2## whereby if R.sup.1a, R.sup.2a, R.sup.3a and R.sup.

Abstract: Renin-inhibiting analogues of formula ##STR1## where X and W are terminal groups optionally with further amino acyl residues; D, E, B and Z (of which any one or except with `reduced` analogues any two may be absent) are aromatic, lipophilic or in the case of E aromatic lipophilic or basic amino acid or amino acid analogue residues; and A is an analogue of a lipophilic or aromatic dipeptide residue wherein the peptide link is replaced by a one- to four-atom carbon or carbon-nitrogen link which as such or in hydrated form is an unhydrolysable tetrahedral analogue of the transition state ##STR2## of peptide bond hydrolysis.

Abstract: A drug release device for inclusion in a parenteral drug delivery system, said device comprising a chamber having an inlet for a liquid administerable to a patient by a parenteral route, a drug dissolution space within said chamber, through which said liquid can be made flow, an outlet for said liquid, and means for receiving and retaining within said drug dissolution space a drug preparation from which a drug is releasable to said liquid during such parenteral delivery, said device characterized in having means for providing the same with one or more durg release cells within which such drug preparation is initially held isolated from the liquid, each of said drug cells having means for emptying its contents of drug preparation into said drug dissolution space after insertion thereof in the drug release device.Such device can be used for sequential emptying of a drug preparation from two or more such drug cells whereby a parenteral liquid dissolves the drug.

Abstract: Novel compounds of the formula I ##STR1## and its salts; process for the preparation thereof, pharmaceutical compositions containing such compounds and their use in medicine to affect gastric acid secretion and provide gastrointestinal cytoprotection.

Abstract: Renin inhibitory polypeptide analogues derived from the natural N-terminal substrate sequence by replacing the amino acid at position 10 with statine or a residue related to it.

Abstract: Peptides wherein an amide bond is replaced by nonhydrolyzable isosteric linkage are disclosed as thrombogenic inhibitors.